Blockbuster Competitors Figure Large Among Biosimilars Under Review in EU
Executive Summary
Amgen’s first biosimilar – a competitor to AbbVie’s Humira – and three would-be competitors to Amgen’s own Neulasta are among the 17 biosimilar products that are under evaluation at the European Medicines Agency.
You may also be interested in...
CHMP Readies ‘Outstanding Issues’ Lists For Products Nearing EU Review End
Baxter, Ariad, Diurnal. Kyowa Kirin and AB Science are among the companies that will likely shortly find out what remaining concerns the European Medicines Agency’s key advisory panel, the CHMP, has regarding products of theirs that are under review.
Amgen’s Biosimilar Adalimumab First To EU Nod But No Launch
Amgen’s biosimilar version of the anti-TNF adalimumab has become the first to receive an EU positive opinion but the company has no plans to launch the product this year.
Amgen’s Biosimilar Adalimumab First To EU Nod But No Launch
Amgen’s biosimilar version of the anti-TNF adalimumab has become the first to receive an EU positive opinion but the company has no plans to launch the product this year.